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Background: National cancer survival statistics are available for the total Australian population but not Indigenous
Australians, although their cancer mortality rates are known to be higher than those of other Australians. We aimed
to validate analysis methods and report cancer survival rates for Indigenous Australians as the basis for regular
national reporting.
Methods: We used national cancer registrations data to calculate all-cancer and site-specific relative survival for
Indigenous Australians (compared with non-Indigenous Australians) diagnosed in 2001-2005. Because of limited
availability of Indigenous life tables, we validated and used cause-specific survival (rather than relative survival) for
proportional hazards regression to analyze time trends and regional variation in all-cancer survival between 1991
and 2005.
Results: Survival was lower for Indigenous than non-Indigenous Australians for all cancers combined and for many
cancer sites. The excess mortality of Indigenous people with cancer was restricted to the first three years after
diagnosis, and greatest in the first year. Survival was lower for rural and remote than urban residents; this disparity
was much greater for Indigenous people. Survival improved between 1991 and 2005 for non-Indigenous people
(mortality decreased by 28%), but to a much lesser extent for Indigenous people (11%) and only for those in remote
areas; cancer survival did not improve for urban Indigenous residents.
Conclusions: Cancer survival is lower for Indigenous than other Australians, for all cancers combined and many
individual cancer sites, although more accurate recording of Indigenous status by cancer registers is required before
the extent of this disadvantage can be known with certainty. Cancer care for Indigenous Australians needs to be
considerably improved; cancer diagnosis, treatment, and support services need to be redesigned specifically to be
accessible and acceptable to Indigenous people.
Keywords: Cancer, Survival, Australia, Australian Aboriginal, Torres Strait Islander, Indigenous Australian, Relative
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Reports from several Australian states and territories indi-
cate that cancer mortality rates are higher for Aboriginal
and Torres Strait Islander peoples (hereafter respect-
fully referred to as “Indigenous Australians”) than other
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reproduction in any medium, provided the orcancer sites [1,2]. These elevations in Indigenous mortality
rates are partly due to higher incidence rates for some
(but not all) cancer sites [3] and partly to lower survival
rates for many cancer sites [4-6]. A recent study in
Queensland reported that five-year cancer survival (all
sites combined) was considerably lower for Indigenous than
non-Indigenous people (50.3% compared to 61.9%) [6].
Until recently no reliable national cancer incidence
or survival statistics have been available for Indigen-
ous Australians. As part of a project auspiced by thel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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national reporting of cancer statistics for Indigenous
Australians, we recently reported the first assessment
of completeness of Indigenous identification in national
cancer registrations data and published seminational
cancer incidence rates (covering 84% of the Indigenous
population); this study confirmed that higher incidence
rates are partly responsible for higher mortality rates
for lung and other smoking-related cancers, and cervix,
uterus, and liver cancers [3]. We now report national
figures for cancer survival for Indigenous Australians.
Population-based cancer survival statistics are usually
calculated using the relative survival method [7]. Relative
survival analysis requires detailed life tables for the general
population to calculate background probability of death.
Relative survival analysis for Indigenous people with
cancer has major limitations because life tables for the
Indigenous population are only available for the single
period 2005-2007 and not available by remoteness category.
Previously published life tables were calculated using an
inappropriate method that produced inconsistent results [8].
We therefore used relative survival analysis to calculate
national cancer survival for Indigenous Australians for the
period 2001-2005 using the 2005-2007 life tables and used
cause-specific survival analysis to examine time trends
over 15 years and compare cancer survival in urban
with rural and remote areas. Relative survival analysis
is the standard method to calculate population-based
survival rates but is not without its limitations; cause-
specific survival analysis is also appropriate in the right
circumstances, particularly if reliable cause of death data
are available [9]. We validated cause-specific analysis by
comparison with relative survival analysis in a restricted
analysis using the limited Indigenous life tables that are
available.
This study and the previously reported seminational
cancer incidence statistics [3] provide a template for regu-
lar national reporting of cancer statistics for Indigenous
Australians.
Methods
Data
Cancer registrations data for all Australians diagnosed with
cancer between 1 January 1991 and 31 December 2005
was obtained from the National Cancer Statistics Clearing
House for the following data items: sex; date of birth;
Indigenous status; remoteness of residence category,
classified in the five categories of the Accessibility/Remote-
ness Index of Australia (ARIA) [10]; date of diagnosis;
cancer site, coded according to the International Classi-
fication of Diseases Version 10 (ICD-10) [11]; date of
death; and underlying cause of death (as recorded by
cancer registries). Information on stage at diagnosis
was not available for most cancer sites.The exclusion criteria were the same as used in the
most recent national report of cancer survival statistics
for Australia; cancers diagnosed at the time of death
were excluded and people diagnosed with multiple primary
cancers were included as multiple records [7]. “Cancer site”
refers to either the location within the body of the primary
tumor, or, for cancers that do not originate at a particular
location (such as cancers of the blood and lymphatic
systems) the morphological type of the cancer. Cancer
site was categorized at the ICD-10 three-digit level with
some sites including multiple related three-digit categories
(e.g., colorectal cancer: C18, C19 and C20) consistent with
those used in the national survival report. Vital status was
verified by matching the national cancer registrations
dataset to the National Death Index for deaths occurring
up to 31 December 2007. To reduce the impact of unreli-
able survival curves for longer follow-up intervals due to
small numbers, we truncated survival times at five years
after diagnosis.
Indigenous status is not included in pathology request/
report forms (the primary source of notifications to cancer
registries), so cancer registers obtain Indigenous status
data from other notification sources (hospitals, radiation
oncology centers, death notifications, etc). The complete-
ness of Indigenous identification varies among the eight
Australian state-based cancer registries; completeness is
high for four registries since 1998 or earlier (New South
Wales, Northern Territory, Queensland, and Western
Australia) but less complete for the other four [3]. All
registries were included in this study. All people identi-
fied as Indigenous were included in the “Indigenous”
category; all others, including those with unknown or
not stated Indigenous status, were included in the
“non-Indigenous” category.
Data from one registry (Victoria) were excluded from
cause-specific analyses because 77% of deceased cases
did not have cause of death recorded; the other seven
states and territories included 94% of the Indigenous
Australian population in 2006 [12]. Cause of death was
coded using the ICD-10 by five cancer registries. One
registry coded cause of death using the International
Classification of Diseases (Oncology) Version 3 (ICD-
O-3) topography codes; [13] these were mapped and
recoded to ICD-10 codes. One registry used ICD-10
codes for most deaths but used ICD-O-3 morphology
codes for deaths caused by cancers of blood and
lymphatic systems. Consequently, for all seven regis-
tries, all deaths from cancers of blood and lymphatic
systems were grouped together and treated as a single
cause of death.
All-cancer and site-specific survival
Cancer survival (i.e., the proportion of cancer cases still
alive) was estimated at one and five years after diagnosis.
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and for specific cancer sites, for cases diagnosed in
2001-2005, which were followed-up to the end of 2007.
Non-Indigenous survival was adjusted to the age distri-
bution of Indigenous cases: for all cancers combined, to
the age-distribution of all Indigenous cases; for specific
cancer sites, to the age-distribution of Indigenous cases
for each site.
For non-Indigenous cases, background population prob-
ability of death by sex, age, and year was obtained from
life tables for the total Australian population published
by the Australian Bureau of Statistics (ABS) [14]. For
Indigenous cases a life table for the period 2005-2007
was used because no consistent time series of life tables
was available for earlier years [15]. Expected survival
was estimated using the Ederer II method [16].
Validation of cause-specific analysis
Relative survival analysis could not be used for some
analyses because appropriate Indigenous life tables were
not available, as described above. Therefore, cause-specific
survival analysis was assessed to see whether it would give
comparable results to relative survival analysis. The cause-
specific survival rate and the relative survival rate estimate
the same measure: the proportion of people that have not
died from their cancer at the specified time after diagnosis.
Cause-specific survival analysis uses only deaths for which
the underlying cause of death is the same as the diagnosed
cancer as the endpoint; relative survival analysis compares
the crude survival rate with the background survival
rate for the general population (adjusted to the age-sex
distribution of the cohort of cancer cases).
For cause-specific analysis, a broad definition of cause-
specific death was applied that included death from:
cancer in the same region of the body as that of the primary
site; cancer of unknown primary cancer site; or unknown
cause. Of deaths counted as cause-specific under this
definition: 88.9% were deaths for which the diagnosis
site and cause of death agreed at ICD-10 three-digit level
or both the diagnosis site and cause of death were cancers
of the blood and lymphatic system; 0.9% were deaths from
other cancers in the same regional grouping as the diagno-
sis site; 8.8% were deaths from cancer of unknown primary
site; and 1.4% were deaths from unknown causes.
Cause-specific was compared with relative survival ana-
lysis for the period 2001-2005, for Australia excluding
Victoria, for all cancers combined, and for specific cancer
sites, separately for Indigenous and non-Indigenous cases.
The survival rates and regression analysis results produced
by the two methods were compared for: the all-cancer
survival rate by year after diagnosis (not adjusted for site
or age); the five-year survival rate for specific cancer
sites (not adjusted for age); and the hazard ratios from
proportional hazards regression (for cause-specific survival)and Poisson regression (for relative survival [17]) models.
Regression models included terms for: Indigenous status;
sex; age at diagnosis; cancer site; year since diagnosis
(as indicator terms); and interaction terms for Indigenous
status with each of age at diagnosis and year since diagno-
sis. Cause-specific analysis was found to be comparable to
relative survival analysis for all cancers combined, but
not for some specific cancer sites (see results). Therefore
time trends and regional variation in cancer survival
were investigated using proportional hazard regression
of cause-specific death rates for all cancers combined and
for the four most prevalent cancer sites in the Indigenous
population (excluding head and neck cancer, for which
cause-specific and relative survival did not produce
similar results).
Regression analysis
Cox proportional hazards regression was used to analyze
cancer mortality of cases diagnosed in 1991-2005 for
Australia, excluding Victoria. The model included terms
for: Indigenous status, sex, age at diagnosis, and ARIA
remoteness category (the four terms of a priori interest);
cancer site; and interaction terms for Indigenous status
with each of age at diagnosis (base age 59 years) and
remoteness categories (base category “major cities”). These
interaction terms were included because the effects of age
at diagnosis and remoteness of residence (but not sex)
were found to be different for Indigenous compared
with non-Indigenous people. Age at diagnosis and ARIA
remoteness category were each included as a single ordinal
term; including them as categorical variables did not
improve model fit. Cancer site was included as multiple
indicator terms. Scaled Schoenfeld residuals, which test
for nonzero slope over time, were used to check if the
proportional hazards assumptions of each variable were
satisfied. A step function of Indigenous status with follow-
up time (as annual intervals) was also included in the
model because the proportional hazards assumption was
not met for Indigenous status, as has been demonstrated
previously [6].
Time trends
For time trends, follow-up was limited to the first two
years after diagnosis because all subjects had at least two
years of potential follow-up (so that shorter follow-up
time for subjects diagnosed late in the study period did
not bias time trends) and because most of the excess
mortality of Indigenous cases occurred in the first two
years after diagnosis (see results). Time trends were ana-
lyzed for all cancers combined (adjusted for cancer site)
and for four of the most prevalent cancer sites in the
Indigenous population: colorectal, lung, breast (female
only), and prostate. Two-year cause-specific survival for
all cancers combined (adjusted for age and cancer site)
Table 1 Demographic characteristics of people diagnosed
with cancer, Australia, 1991-2005
Indigenous Non-indigenous
n = 7,019 n = 1,228,573
Percent of column total
Sex
Male 47.8 55.0
Female 52.2 45.0
Age at diagnosis
0 to 49 years 28.9 15.1
50 to 59 years 23.1 15.7
60 to 69 years 24.4 24.0
70 years and over 23.6 45.2
Median age (years) 59 68
State of residence
Queensland 30.7 18.8
New South Wales 27.8 34.4
Western Australia 16.2 8.9
Northern Territory 15.5 0.4
Victoria 4.8 24.7
South Australia 4.1 8.8
Tasmania 0.6 2.7
Australian Capital Territory 0.3 1.3
Remoteness of residence
Major cities 27.3 65.9
Inner regional 15.8 22.5
Outer regional 25.3 9.8
Remote 11.2 1.1
Very remote 19.8 0.4
Other1 0.7 0.4
Vital status at 31/12/2007
Alive 33.4 45.1
Dead 66.6 54.9
1Includes migratory and unknown.
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ARIA category. Multivariate analysis was performed using
proportional hazards regression. The model included terms
for: Indigenous status, sex, age at diagnosis, and year of
diagnosis (the terms of a priori interest); cancer site (for
analysis of all cancers combined); and interaction terms for
Indigenous status with each of age at diagnosis and year of
diagnosis. Variation in time trend by remoteness category
was investigated by including an interaction term for ARIA
category by year in separate models for Indigenous and
non-Indigenous cases.
All analyses were performed using Stata (versions 11.1
and 12.1) [18]. Relative survival analysis was performed
using the ‘strs’ procedures of Stata [17]. Ethics approvals
were obtained from 12 human research ethics commit-
tees covering all states and territories, including several
Indigenous committees or subcommittees. Approval to
use cancer registrations data was obtained from each of
the eight Australian cancer registries.
Results
1,235,592 Australians diagnosed with invasive cancer
between 1991 and 2005 met the inclusion criteria for
this study; 0.6% were identified as Indigenous (Aboriginal
and/or Torres Strait Islander peoples) (Table 1). Indigen-
ous cases were more likely to be female, younger, and live
outside major cities. A higher proportion of Indigenous
(67%) than non-Indigenous (55%) cases died by the end
of 2007.
Survival rates
For all cancers combined (adjusted for age), survival was
lower for Indigenous than other Australians (Table 2).
Most of the difference arose during the first year after
diagnosis; survival was 63.8% for Indigenous compared
with 83.4% for non-Indigenous cases at one year after
diagnosis and 46.7% compared with 70.0% at five years.
Survival was lower for Indigenous than non-Indigenous
cases for almost all cancer sites at both one and five
years after diagnosis.
Cause-specific compared with relative survival
For all cancers combined, cause-specific survival was
similar to relative survival for both Indigenous and
non-Indigenous cases throughout the first five years after
diagnosis, with cause-specific survival slightly higher than
relative survival (Figure 1). For non-Indigenous cases
cause-specific and relative survival were 80.1% (95% CI
80.0-80.3) compared with 79.1% (78.9-79.2) at one year
and 65.6% (65.4-65.8) compared with 64.6% (64.4-64.8) at
five years, while for Indigenous cases 64.7% (63.0-66.4)
compared with 63.2% (61.4-64.9) at one year and 47.0%
(45.0-48.9) compared with 45.8% (43.7-47.9) at five years.
Results of cause-specific analysis using proportional hazardsregression were similar to those of relative survival analysis
using Poisson regression (Table 3, Additional file 1: Table
S3a); hazard ratios were similar for all terms included in
the models (with the same terms in each model). For
specific cancer sites, the cause-specific survival rate was
similar to the relative survival rate for most sites but very
different for some; differences were greater for Indigenous
than non-Indigenous cases (see Additional file 2: Table
S7). Cause-specific analysis was therefore restricted to
analysis of all cancers combined and selected cancer sites.
Regression analysis
For all cancers combined, the cause-specific death rate
was higher (i.e., cancer survival was lower) for males
Table 2 One-year and five-year relative survival1 by Indigenous status and cancer site/type, Australia, 2001-2005
Indigenous Non-indigenous2
Cases One-year Five-year Cases One-year Five-year
Cancer site/type n % (95% CI) % (95% CI) n % (95% CI) % (95% CI)
Head and neck (C1-14, C30-32) 236 60.3 (53.6-66.4) 32.4 (25.6-39.5) 11 893 86.1 (85.5-86.8) 65.9 (64.9-66.9)
Stomach (C16) 73 39.8 (28.3-51.1) 16.9 (8.0-29.0) 9 349 56.1 (55.1-57.1) 30.7 (29.6-31.7)
Colorectal (C18-20) 306 80.1 (74.8-84.6) 58.5 (50.9-65.7) 62 021 85.6 (85.3-85.9) 66.3 (65.9-66.8)
Anus (C21) 22 73.8 (49.9-88.0) 49.1 (20.9-73.8) 1 304 91.7 (89.9-93.1) 70.4 (67.3-73.4)
Liver (C22) 83 24.8 (16.0-34.6) 11.2 (5.1-20.0) 4 500 43.4 (41.9-44.9) 19.9 (18.5-21.2)
Pancreas (C25) 91 26.3 (17.6-35.9) 11.2 (5.4-19.5) 9 667 27.6 (26.7-28.5) 7.6 (7.0-8.3)
Lung (C33-34) 500 29.4 (25.4-33.5) 9.1 (6.3-12.5) 42 139 43.4 (42.9-43.9) 16.7 (16.3-17.2)
Melanoma (C43) 59 95.6 (84.4-100.7) 73.8 (55.5-88.5) 48 592 97.9 (97.7-98.1) 92.4 (91.9-92.8)
Breast (C50) 420 94.1 (91.0-96.4) 80.1 (74.3-85.2) 59 640 97.9 (97.7-98.0) 89.5 (89.1-89.8)
Cervix (C53) 109 79.8 (70.8-86.5) 57.6 (46.6-67.4) 3 475 90.8 (89.7-91.7) 78.3 (76.7-79.8)
Uterus (C54) 96 85.2 (75.9-91.4) 78.7 (66.7-88.2) 7 969 94.0 (93.5-94.6) 84.6 (83.6-85.7)
Ovary (C56) 53 77.1 (62.9-86.8) 50.1 (33.6-65.1) 5 777 83.5 (82.5-84.5) 53.1 (51.6-54.6)
Prostate (C61) 181 90.4 (84.0-94.9) 83.6 (72.5-93.2) 68 475 97.3 (97.1-97.4) 91.0 (90.6-91.4)
Testis (C62) 25 100.5 (100.5-100.5) 94.5 (73.6-100.5) 3 209 98.8 (98.3-99.2) 96.9 (96.0-97.6)
Kidney (C64) 69 77.5 (65.2-86.3) 68.1 (53.0-80.7) 10 522 84.9 (84.2-85.6) 73.2 (72.1-74.2)
Bladder (C67) 53 61.5 (46.4-74.0) 54.7 (36.1-72.6) 11 270 85.2 (84.5-85.9) 68.1 (66.9-69.2)
Brain (C71) 48 58.9 (43.6-71.4) 42.2 (26.9-56.9) 6 800 64.3 (63.2-65.5) 40.4 (39.2-41.7)
Thyroid (C73) 74 93.0 (83.9-97.5) 85.0 (69.3-94.5) 6 809 97.0 (96.5-97.4) 96.0 (95.3-96.6)
Hodgkin lymphoma (C81) 26 96.8 (76.2-100.1) 100.6 (79.2-104.0) 2 290 96.0 (95.1-96.8) 90.3 (88.8-91.7)
NHL (C82-85, C96) 101 67.4 (56.9-76.1) 52.0 (37.3-65.8) 18 392 85.5 (85.0-86.0) 73.7 (72.9-74.5)
Leukemia (C91-95) 108 64.6 (54.5-73.1) 53.7 (42.7-63.9) 12 864 80.3 (79.5-81.0) 63.9 (62.9-64.9)
Unknown primary (C76-80) 196 29.2 (22.8-35.8) 14.9 (9.9-21.1) 14 997 35.6 (34.9-36.4) 21.3 (20.6-22.1)
Other 363 61.1 (55.7-66.1) 40.3 (34.4-46.2) 42 463 78.5 (78.1-78.9) 57.2 (56.7-57.8)
All cancers (C00-96, D45-47) 3 292 63.8 (62.1-65.5) 46.7 (44.6-48.7) 464 417 83.4 (83.3-83.5) 70.0 (69.8-70.2)
1Relative survival rate.
2Age-adjusted to age distribution of Indigenous cases for each cancer site.
Figure 1 Cause-specific compared with relative survival, all cancers combined by Indigenous status, Australia (excluding Victoria), 2001-2005.
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Table 3 Cause-specific compared with relative survival
regression analysis1, all cancers combined, Australia
(excluding Victoria), 2001-2005
Relative Cause-specific
HR2 (95% CI) HR (95% CI)
Indigenous
1st year after diagnosis 1.88 (1.77-2.00) 1.94 (1.82-2.06)
2nd year after diagnosis 1.63 (1.43-1.85) 1.64 (1.45-1.86)
3rd year after diagnosis 1.66 (1.35-2.03) 1.62 (1.35-1.95)
4th year after diagnosis 1.42 (1.02-1.96) 1.66 (1.28-2.15)
5th year after diagnosis 0.65 (0.30-1.38) 0.96 (0.60-1.52)
Sex
Female 0.92 (0.91-0.93) 0.92 (0.91-0.94)
Age at diagnosis (per year of age)
Non-indigenous 1.03 (1.03-1.03) 1.03 (1.03-1.03)
Indigenous 1.02 (1.01-1.02) 1.02 (1.01-1.02)
1Both models were also adjusted for cancer site (see Additional file 1: Table S3a).
2Hazard ratio.
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than urban residents (Table 4, Additional file 3: Table S4a).
The effects of age at diagnosis and remoteness were differ-
ent for Indigenous than non-Indigenous cases. The death
rate increased by 3% per year of age for non-Indigenous
cases but by 2% for Indigenous cases; this was because
death rates were relatively high for younger Indigenous
cases. Death rates were higher for those resident in very
remote compared with metropolitan areas: 23% higher forTable 4 Regression analysis1 of cause-specific mortality
for all cancers combined, Australia (excluding Victoria),
1991-2005
HR2 (95%CI)
Indigenous3
1st year after diagnosis 1.50 (1.41-1.60)
2nd year after diagnosis 1.23 (1.11-1.35)
3rd year after diagnosis 1.21 (1.07-1.38)
4th year after diagnosis 1.16 (0.98-1.37)
5th year after diagnosis 0.99 (0.79-1.23)
Sex
Female 0.93 (0.92-0.93)
Age at diagnosis (per year of age)
Non-indigenous 1.03 (1.03-1.03)
Indigenous 1.02 (1.02-1.02)
Remoteness (per ARIA category)
Non-indigenous 1.05 (1.05-1.06)
Indigenous 1.13 (1.11-1.16)
1The model was also adjusted for cancer site (see Additional file 3: Table S4a).
2Hazard ratio.
3Applies to the reference categories of the interaction terms (i.e., people of
median age 59 years and resident in major cities).non-Indigenous but 65% higher for Indigenous cases.
The effect of sex was similar in Indigenous and non-
Indigenous cases; the hazard ratio for an interaction term
for Indigenous status by sex was not statistically signifi-
cant, so an interaction term for “Indigenous status by sex”
was not included in the final model.
Time trend in two-year survival rate
Cancer survival improved considerably for non-Indigenous
cases, but less so for Indigenous cases. The death rate in
the first two years after diagnosis decreased by 2% per year
for non-Indigenous (28% decrease over 15 years), but by
only 1% per year for Indigenous cases (11% over 15 years)
(Table 5, Additional file 4: Table S5a).
For non-Indigenous cases this decrease over time was
similar for all ARIA categories (hazard ratio [HR] for
interaction term “year by ARIA category”: 1.00, 95% CI
1.00-1.00) (see Additional file 5: Table S8). For Indigenous
cases survival increased for residents of remote and very
remote areas but not for urban residents (Figure 2). This
was confirmed by multivariate analysis (see Additional
file 5: Table S8); the time trend was different for urban
compared with rural and remote residents (HR for
interaction term “year by ARIA category”: 0.992, 95%
CI 0.986-0.998). The death rate decreased over time for
Indigenous cases residing in more remote areas, by
26% between 1991 and 2005 in the “very remote” ARIA
category (HR 0.98 per year, 95% CI 0.97-0.99), but did
not decrease over time for Indigenous cases resident in
the “major metropolitan” ARIA category (HR 1.01, 95%
CI 0.99-1.03).Table 5 Time trends: regression analysis1 of
cause-specific mortality in two years after diagnosis for
all cancers combined, Australia (excluding Victoria),
1991-2005
HR2 (95% CI)
Indigenous3 1.54 (1.42-1.66)
Sex
Female 0.95 (0.94-0.95)
Age at diagnosis (per year of age)
Non-indigenous 1.03 (1.03-1.03)
Indigenous 1.02 (1.02-1.02)
Remoteness (per ARIA category)
Non-indigenous 1.06 (1.06-1.07)
Indigenous 1.16 (1.13-1.19)
Year of diagnosis (per year)
Non-indigenous 0.98 (0.98-0.98)
Indigenous 0.99 (0.98-1.00)
1The model was also adjusted for cancer site (see Additional file 4: Table S5a).
2Hazard ratio.
3Applies to the reference categories of the interaction terms (i.e., people of
median age 59 years in 2005).
Figure 2 Two-year cause-specific survival rate by year of diagnosis, all cancers combined, indigenous by ARIA category and
non-indigenous, Australia (excluding Victoria), 1991-2005.
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prevalent cancers in the Indigenous population: colorectal,
lung, breast (female only), and prostate (Table 6). For
non-Indigenous cases death rates decreased for all four
cancers. For Indigenous people with colorectal and breast
cancer, death rates decreased to a similar extent as for
non-Indigenous cases, but there was no decrease for lung
and prostate cancer.
Discussion
Survival is lower for Indigenous than other Australians
with cancer, for all sites combined, and for many individual
cancer sites. This disparity is greatest immediately after
diagnosis, greater for remote than metropolitan residents,
greater for younger than older people, and is increasing
over time.Table 6 Time trends: regression analysis of cause-specific mo
hazard ratio (95% confidence interval), Australia (excluding V
Colorectal Lung
Indigenous1 1.44 (1.05-1.97) 1.42 (1.
Sex
Female 1.02 (1.00-1.04) 0.90 (0.
Age at diagnosis
Non-indigenous 1.03 (1.02-1.03) 1.02 (1.
Indigenous 1.00 (0.99-1.01) 1.01 (1.
Remoteness (per ARIA category)
Non-indigenous 1.08 (1.06-1.09) 1.07 (1.
Indigenous 1.19 (1.07-1.33) 1.08 (1.
Year of diagnosis (per year)
Non-indigenous 0.97 (0.97-0.98) 0.99 (0.
Indigenous 0.97 (0.94-1.00) 1.00 (0.
1Applies to the reference categories of the interaction terms (i.e., people of medianCause-specific survival analysis
Although not without potential limitations, [9] relative
survival is the preferred method for population-based
cancer survival analysis (as distinct from clinical studies)
because of concerns about accuracy of classification of
cause of death, and because for many cancer cases, cancer
is not the only condition contributing to their death.
However, the inadequacies of life tables for the Australian
Indigenous population limit the applicability of the relative
survival method for analysis of time-trends and variation
by remoteness of residence. The ABS has determined
that the non-standard methods used to calculate Indi-
genous life tables before 2005 [19] were unreliable and
produced considerably inaccurate results [20]. The ABS
has subsequently published Indigenous life tables for
2005-2007 using the standard method used for the totalrtality in two years after diagnosis for specific cancers,
ictoria), 1991-2005
Breast Prostate
21-1.66) 1.66 (1.06-2.61) 5.59 (3.15-9.94)
89-0.92) n/a n/a
02-1.02) 1.04 (1.04-1.04) 1.08 (1.08-1.08)
01-1.02) 1.00 (0.99-1.02) 1.02 (1.00-1.05)
06-1.08) 1.06 (1.03-1.10) 1.13 (1.10-1.16)
03-1.14) 1.29 (1.13-1.48) 1.35 (1.12-1.64)
99-0.99) 0.96 (0.95-0.96) 0.96 (0.95-0.96)
98-1.02) 0.97 (0.92-1.02) 1.06 (0.99-1.13)
age 59 years in 2005).
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spective time series [15] or published Indigenous life
tables stratified by remoteness category (but is expected
to do so in late 2013).
Life tables stratified by Indigenous status also have a
potential for differential misclassification of Indigenous
status between the life tables and the cancer registration
data. If, for example, Indigenous status was less complete
in the deaths data used to calculated probability of death
in life tables than in cancer registers, the life tables would
underestimate probability of death for the background
Indigenous population, and consequently, relative survival
analysis would underestimate cancer survival. Death
and cancer registers both rely on death notifications
and hospital records (for deaths occurring in hospital)
for Indigenous status data, so this potential differential
misclassification may not be large, but there is no evidence
available to test this.
Over time, improvements in the accuracy of Indigenous
mortality data may provide more detailed and consistent
Indigenous life tables that will enable use of relative sur-
vival for more detailed analysis of survival for Indigenous
people with cancer. In the interim, our comparison of
cause-specific with relative survival analysis indicates that
cause-specific analysis is as reliable as relative survival
for analysis of time trends and regional variation in cancer
survival for all cancers combined and some specific
cancer sites.
For all cancers combined and for most cancer sites
relative survival and cause-specific survival produced simi-
lar results (see Additional file 2: Table S7 and Additional
file 5: Table S8), but for some specific sites such as
head and neck, bladder, and leukemia the two methods
produced very different results. Where there was a large
difference between the two methods, cause-specific
survival was mostly higher than relative survival. Under-
estimation of cancer-related deaths for people with these
cancers would produce this effect, either because deaths
due to cancer were misclassified or a high proportion of
deaths were partially attributable to these cancers but few
were classified as cancer deaths [9]. Alternatively, for these
sites relative survival might be underestimated because
the probability of noncancer related death for people with
these cancers is higher than for the general population.
This is plausible for head and neck cancer and bladder
cancer because they are smoking-related, and the prob-
ability of noncancer death for people with these cancers
would be higher than that of the general population (most
of whom are not smokers). However, this is not consistent
with the results for other smoking-related cancers such
as lung and pancreas, for which relative and cause-
specific survivals were similar. It is not obvious why
relative and cause-specific survivals are so different for
some cancer sites.Limitations
Identification of Indigenous people in cancer registrations
data is known to be high for four of the eight registries
included in this study (New South Wales, Northern
Territory, Queensland, and Western Australia), which
cover 84% of the Indigenous population [3]. We have
included data from the other four registries with low
identification of Indigenous people (Australian Capital
Territory, South Australia, Tasmania, and Victoria) (Table 1).
Consequently it is likely that a proportion of Indigenous
people were misclassified as non-Indigenous in this study.
Indigenous cases comprised 0.6% of cases, which is less
than the proportion of Indigenous people in the total
Australian population (0.9% in the 50+ age-group in 2006),
[12] but cancer incidence is different for many cancer sites
for Indigenous than other Australians, including being
lower for several of the most common cancers (breast,
colon and rectum, prostate, and melanoma) [3] so a direct
comparison of population proportions is not informative.
We estimate that up to 0.2% of the non-Indigenous group
may be misclassified Indigenous cases, indicating that
up to 25% of Indigenous cases may be misclassified as
non-Indigenous. If misclassified Indigenous cases had
similar cancer survivals to other Indigenous cases, then
the Indigenous survivals reported here are unbiased. If
misclassified Indigenous cases had better survival than
those correctly classified as Indigenous, perhaps because
those incorrectly classified had better social, economic
and environmental circumstances than those correctly
classified as Indigenous, the Indigenous survivals reported
here would be an underestimate to a small extent. Includ-
ing misclassified Indigenous cases in the non-Indigenous
group would have had an insignificant effect on non-
Indigenous survival.
This study does not include people diagnosed with
cancer after 2005, and follow-up of vital status after
2007, because national coded data on cause of death
produced by the ABS has not been available to cancer
registries since 2007 when data providers decided that
the previous process to request and approve data access
was no longer adequate. Efforts to develop a new approval
process have been underway for several years but have
not yet been successful [21]. Until cause of death data
becomes available to cancer registers again, cause-specific
cancer survival for Indigenous Australians cannot be up-
dated for recent years.
One potentially large source of bias in this study is an
information bias arising because Indigenous status in
cancer registration data is partially derived from deaths
data. The primary source of case ascertainment, pathology
reports, does not include Indigenous status. Cancer registers
rely on notifications from hospitals and death registrations
as their main sources of Indigenous status data. If notifica-
tions from hospitals are significantly incomplete, people
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will introduce differential misclassification of Indigenous
status; Indigenous cases who have died will be more likely
to be identified as Indigenous than Indigenous cases who
have not died. The national cancer registration dataset
does not include data on the source(s) of Indigenous
status for each cancer registration, so the extent of this
potential bias could not be assessed by this study; this
requires specific investigation with cancer registries.
Reasons for lower survival
This study confirms, at the national level, previous reports
from individual states/territories that cancer survival is
lower for Indigenous than other Australians [4,22,23].
These studies have found that Indigenous people are
more likely to have advanced disease when diagnosed,
more likely to have chronic disease comorbidity, and
less likely to be offered, choose, and complete curative
treatment. However, these factors only partly explained
the lower survival of Indigenous people suggesting that
other unmeasured factors were also involved. These
might include the less advantageous social, educational,
economic, and environmental circumstances of many
Indigenous Australians [1].
Excess mortality of Indigenous (compared with non-
Indigenous) cancer cases was greatest in the first year
after diagnosis; by the fifth year Indigenous cases had no
excess mortality. This confirms at the national level a
similar finding reported from Queensland [6]. This may
reflect delayed cancer diagnosis (with more Indigenous
cases having disseminated disease when diagnosed), lower
access to curative cancer treatment, or higher levels of
chronic disease comorbidity that complicate or preclude
cancer treatment; all these factors have been reported as
more common for Indigenous than other Australians
[2,23]. The information bias arising from Indigenous
cases being differentially identified from death certificates
(described above) might also partly explain this finding,
although cases diagnosed at the time of death were
excluded from this analysis so it is not obvious how this
bias would operate more in the first year after diagnosis
than in later years. This needs to be further investigated.
Remoteness of residence was associated with lower
survival. For Indigenous cases this disparity was very large;
death rates were 65% higher for Indigenous people in very
remote areas than in major cities. Thirty-one percent
of Indigenous cases live in remote or very remote areas,
compared to only 1% of non-Indigenous cases, so remote-
ness is a particularly serious detrimental factor for Indigen-
ous people with cancer. Survival increased for Indigenous
cases in remote areas, but in 2005 was still lower than
for urban Indigenous cases, for whom survival had not
improved at all. Survival improved considerably for
non-Indigenous cancer cases, with a 28% decrease indeath rate between 1991 and 2005. Improvements in
cancer diagnosis, treatment and support services that have
been successful in improving cancer outcomes for most
Australians in recent years have apparently been less
effective for Indigenous people. Access to, and acceptabil-
ity of, diagnosis and treatment services are likely to be
part of the explanation for the geographic disparity; the
previous studies cited above provide little information
about this. Further investigation of the reasons for the
very poor survival of cancer cases from rural and remote
areas, and how to overcome them, should be a high prior-
ity for both Indigenous and non-Indigenous people.
Population screening can lead to overdiagnosis of cancers
that would not have otherwise been diagnosed before
the person died from other causes. This may account for
some of the improvement in survival for non-Indigenous
Australians for breast and prostate cancers and to a lesser
extent colorectal cancer over the period of this study,
during which screening for these cancers became more
common (screening for colorectal cancer increased more
recently). Indigenous Australians have lower cancer screen-
ing participation, [2,24] so they may be less susceptible
to this overdiagnosis effect. There was little evidence of
such an effect for breast and colorectal cancers in this
study; the time trend in death rates was similar for Indigen-
ous and non-Indigenous cases for both cancers (Table 6),
but for prostate cancer the death rate decreased for
non-Indigenous cases but not for Indigenous cases, which
would be consistent with increasing overdiagnosis of
prostate cancer among non-Indigenous cases only. For
all cancers combined excluding these three screened
cancers, the time trend for death rates (HR per year:
non-Indigenous 0.97, Indigenous 0.98) was similar to
that when the screened cancers were included (non-
Indigenous 0.98, Indigenous 0.99).
In recent years there has been increased attention to
the disadvantage suffered by Indigenous people with cancer.
In 2010 Cancer Australia (the Australian Government’s
cancer agency) commissioned a report on research pri-
orities for Indigenous cancer control, [25] although it is
still considering what action to take. A national roundtable
on cancer control research for Indigenous Australians,
convened in the same year by a senior Indigenous
researcher, [26] led to the establishment of a national
Centre of Research Excellence in Indigenous cancer
control in 2012 [27]. The Centre has already established
a National Indigenous Cancer Network of Indigenous
cancer survivors and other community members, health
professionals, and researchers [28]. Cancer services have
started initiatives to improve cancer care in rural areas,
such as the establishment of radiation oncology services in
regional centres such as Darwin and Townsville [29] and
use of telemedicine to provide access from remote com-
munities to specialist oncologists [30]. Regular reporting
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to determine whether these initiatives are working.Conclusions
Cancer survival is lower for Indigenous than other
Australians, for all cancers combined, and many indi-
vidual cancer sites. This disparity is greatest in remote
areas and has increased over time because survival for
Indigenous people has not improved as much as for
Australians generally. Cancer survival statistics for the
total Australian population do not necessarily apply to
Indigenous Australians who develop cancer; more specific
information is needed to assist them in making import-
ant treatment and personal decisions and to assess the
effectiveness of efforts to reduce this disparity. Cancer
registration data can be used to produce regular national
survival statistics for Indigenous Australians, as they are
for Australians generally. Despite data limitations, reliable
statistics on cancer survival for Indigenous Australians
can and should be reported on a regular basis by national
and state/territory cancer statistics agencies.Additional files
Additional file 1: Table S3a. Cause-specific compared with relative
survival regression analysis, all cancers combined, Australia (excluding
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ratios for specific cancer sites.
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Australia (excluding Victoria) 1991-2005 (full model). Description: Table S5
including hazard ratios for specific cancer sites.
Additional file 5: Table S8. Regression analysis for all cancers
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